At a glance
ClinicalIndex Comparison RecordN/ACompleted· 36 enrolled
Drug / intervention
Rizatriptan +1 moredrug
Likely dose
Rizatriptan 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs
In Brief
A clinical study evaluating Rizatriptan and Placebo for Migraine. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedAug 2006
Primary CompletionJan 2009
Study CompletionMar 2010
TodayJul 2026
First PostedAug 4, 2006
Enrollment StartAug 1, 2006
Primary CompletionJan 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.9 years ago
Interventions
Rizatriptandrug
10 mg Rizatriptan in an unlabeled pill given once on one of two visits
Placeboother
In an unlabeled pill given once on one of two visits.